Month: November 2022

Reaction kinetics of trioxane synthesis from formaldehyde catalyzed by sulfuric acid/ionic liquid was written by Xie, Hui;Lv, Li;Zhang, Tao;Tang, Shengwei. And the article was included in Reaction Kinetics, Mechanisms and Catalysis in 2021.Electric Literature of C10H20N2O4S The following contents are mentioned in the article:

The composite catalyst composed of sulfuric acid and alkyl imidazole-based acidic ionic liquid was used to replace pure sulfuric acid as the catalyst for the synthesis of trioxane. 1-ethyl-3-methylimidazolium hydrosulfate ([EMIM][HSO₄]), 1-butyl-3-methylimidazolium hydrosulfate ([BMIM][HSO₄]), and 1-hexyl-3-methylimidazole hydrosulfate ([HMIM][HSO₄]) were chosen to form composite catalysts with sulfuric acid. The effects of ionic liquid types, formaldehyde concentration (35 鈭?55 wt%), and temperature (353 鈭?368 K) on the reaction were studied. When H₂SO₄ / [EMIM][HSO₄] was used as catalyst with a dosage of 0.6 mol/kg of formaldehyde solution, the optimal catalytic performance was obtained at 373 K with the 50 wt% formaldehyde solution as initial reactant. Compared to that with pure H₂SO₄ as the catalyst, the trioxane concentration in the reaction system was sharply increased with an increment of 17% by the synergy of ionic liquid [EMIM][HSO₄]. The equilibrium constant was increased from 3.08 x 10^-5 to 4.19 x 10^-5 by the addition of [EMIM][HSO₄]. The reaction was intensified by the inhibition of reverse reaction. It indicates that the addition of [EMIM][HSO₄] has complicated effects on the reaction. The research results provide a deep understand for the catalytic performance of mineral acid/ionic liquid composite catalysts. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Electric Literature of C10H20N2O4S).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Electric Literature of C10H20N2O4S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A ‘two-in-one’ crystal having two different dimensionality in the extended structures: A series of cadmium(II) coordination polymers from V-shaped organic linkers was written by Ramathulasamma, Mukara;Bommakanti, Suresh;Das, Samar K.. And the article was included in Polyhedron in 2021.Application In Synthesis of 3,5-Di(1H-imidazol-1-yl)pyridine The following contents are mentioned in the article:

Three Cd(II) containing coordination polymers, formulated as {Cd(oba)(biip)}_n路nH₂O (1), {Cd(sdba)(biip)}_n路n5H₂O (2) and {[Cd_1.5(hfipbb)₂(biip)_1.5(H₂O)][Cd(hfipbb)(biip)]}_n路n2H₂O (3), were synthesized by using ditopic V-shaped ligands i.e., H₂oba (4,4′-oxydibenzoic acid), H₂sdba (4,4′-thiodibenzoic acid), H₂hfipbb {4,4′-(perfluoropropane-2,2-diyl)dibenzoic acid} and an auxiliary linker, biip [3,5-di(1H-imidazol-1-yl)pyridine] under solvothermal conditions. Compounds 1–3 are characterized by single crystal X-ray diffraction anal., IR spectroscopy, thermogravimetric (TG) and elemental analyses. Compound 1 contains a 3D framework, formed by the connectivity of {CdO₄N₂} secondary building unit (SBU) with the organic linkers, whereas compound 2 is a 2D coordination polymer. Interestingly, unlike to compounds 1 and 2, compound 3 possesses a distinctive structural feature having two crystallog. independent polymeric motifs (polymers, A and B) having two different dimensionality within the same crystal, i.e., coordination polymer A (CP-A) that forms a one-dimensional motif and coordination polymer B (CP-B), which has a two-dimensional structure. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Application In Synthesis of 3,5-Di(1H-imidazol-1-yl)pyridine).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Application In Synthesis of 3,5-Di(1H-imidazol-1-yl)pyridine

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. was written by 脰zt眉rk, Kadir;Kurt, 脰mer;脟elebi, G眉rkan;艦arlak, Hakan;Karakaya, Muhammed Fatih;Demirci, Hakan;K谋l谋n莽, Ali;Uygun, Ahmet. And the article was included in The Turkish journal of gastroenterology in 2020.Application of 117976-90-6 The following contents are mentioned in the article:

BACKGROUND/AIMS: Although many regimens, including quadruple, sequential, and concomitant treatment, are used and recommended as first-line or rescue therapies for Helicobacter pylori infection, eradication rates are still below 90% in intention-to-treat analyses. Treatment protocols with substantially high eradication rates and low antibiotic resistance are needed. In this study, we investigated the efficacy of high-dose dual therapy as first-line treatment in a Turkish population. MATERIALS AND METHODS: All patients underwent upper gastrointestinal endoscopy for the initial H. pylori status because of dyspeptic symptoms. All patients received a 14-day, high-dose dual therapy comprising rabeprazole (20 mg t.i.d.) and amoxicillin (1 g t.i.d.) for H. pylori eradication. H. pylori stool antigen tests of eradication were administered to all participants at least 4 weeks after the completion of the treatment. RESULTS: The high-dose dual therapy demonstrated a 91.3% rate of successful eradication of H. pylori infection. Per-protocol success was 94.4% among female patients (n=51) and 89.6% among male patients (n=86); in terms of gender, the differences were not significant (p=0.310). No side effects were observed during the study in any patient. Six other patients did not take adequate doses of the treatment protocol. CONCLUSION: High-dose dual therapy with rabeprazole and amoxicillin was highly effective and well tolerated as a first-line therapy for H. pylori eradication. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Application of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Application of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Nitrolysis of hexamethylenetetramine in presence of ionic liquids was written by Wang, Nai;Shi, Yu;Yang, Hong-wei;Chen, Guang-bin;Lu, Chun-xu. And the article was included in Hanneng Cailiao in 2011.Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate The following contents are mentioned in the article:

Direct nitrolysis of hexamethylenetetramine catalyzed by ionic liquids was studied. The effects of dosage of ionic liquid and different ionic liquids on the nitrolysis were investigated in the systems of 95% nitric acid and nitrogen pentoxide/nitric acid. In the system of 95% nitric acid, [Hmim]NO₃ shows the best catalytic activity in all of ionic liquids screened. The optimal reaction condition is 1.5mol% ionic liquid loading, 12 : 1 of quality ratio of 95% nitric acid to hexamethylenetetramine and 90 min of reaction time at -5-0 °C. 1,3,5-Tri-nitroperhydro-1,3,5-triazine can be obtained in yield of 75.9% using ionic liquid as catalyst under optimized condition, while 1,3,5-tri-nitroperhydro-1,3,5-triazine can be generated in lower yield of 68.3% without adding ionic liquid In the system of nitrogen pentoxide/nitric acid, [Bmim]BF₄ shows the best catalytic activity. The optimal reaction conditions are 5mol% ionic liquid loading, 9 : 1 of mass ratio of 100% nitric acid to hexamethylenetetramine, 2 : 1 of quality ratio of 100% hexamethylenetetramine to nitrogen pentoxide and 60 min of reaction time at -5-0 °C. Under optimized conditions, 77.6% yield of 1,3,5-tri-nitroperhydro-1,3,5-triazine can be obtained without adding ionic liquid, while yield of 1,3,5-tri-nitroperhydro-1,3,5-triazine can be improved to 85.4% using ionic liquid as catalyst. It indicates that ionic liquids have observably catalytic activity on the direct nitrolysis of hexamethylenetetramine. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Study on mechanism of ionic liquid for methane plasma conversion using spectra method was written by Zhang, Xiu-ling;Zhou, Qian;Di, Lan-bo;Yu, Miao. And the article was included in Guangpuxue Yu Guangpu Fenxi in 2012.Recommanded Product: 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate The following contents are mentioned in the article:

C₆MIMBF₄, C₆MIMCF₃COO and C₆MIMHSO₄ were introduced into a d.c. discharge plasma system resp. for methane conversion. The kinds of active species and relative intensity of spectral peaks were detected through online spectrum diagnosis technique of optical emission spectroscopy. Mechanism of ionic liquid for methane conversion in gas-liquid plasma was investigated. The results showed that a spatially and temporally stable gas-liquid interface was obtained in ionic liquid incorporated plasma system. With introduction of ionic liquid, methane conversion and C₂ hydrocarbons yields increased. The C₂ hydrocarbon selectivity greatly increased when C₆MIMCF₃COO and C₆MIMBF₄ were introduced to the plasma, and decreased when C₆MIMHSO₄ was used. Active species like C, C₂, C₃, CH and H were detected in gas-liquid plasma system of methane discharge. Compared with the absence of ionic liquid in the plasma system, the relative intensity of spectral peaks of most active species increased when ionic liquid was introduced into the plasma system. ¹H NMR results showed that the structure of ionic liquid kept stable during plasma discharge progress. Those indicated that ionic liquid could improve the plasma discharge intensity. At the same time, ionic liquid showed good catalytic activity in gas-liquid surface reaction. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Recommanded Product: 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Recommanded Product: 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Autoimmune hemolytic anemia: causes and consequences was written by Fattizzo, B.;Barcellini, W.. And the article was included in Expert Review of Clinical Immunology in 2022.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

A review. Autoimmune hemolytic anemia (AIHA) is classified according to the direct antiglobulin test (DAT) and thermal characteristics of the autoantibody into warm and cold forms, and in primary vs. secondary depending on the presence of associated conditions. AIHA displays a multifactorial pathogenesis, including genetic (association with congenital conditions and certain mutations), environmental (drugs, infections, including SARS-CoV-2, pollution, etc.), and miscellaneous factors (solid/hematol. neoplasms, systemic autoimmune diseases, etc.) contributing to tolerance breakdown. Several mechanisms, such as autoantibody production, complement activation, monocyte/macrophage phagocytosis, and bone marrow compensation are implicated in extra-/intravascular hemolysis. Treatment should be differentiated and sequenced according to AIHA type (i.e. steroids followed by rituximab for warm, rituximab alone or in association with bendamustine or fludarabine for cold forms). Several new drugs targeting B-cells/plasma cells, complement, and phagocytosis are in clin. trials. Finally, thrombosis and infections may complicate disease course burdening quality of life and increasing mortality. Beyond warm and cold AIHA, a gray-zone still exists including mixed and DAT neg. forms representing an unmet need. AIHA management is rapidly changing through an increasing knowledge of the pathogenic mechanisms, the refinement of diagnostic tools, and the development of novel targeted and combination therapies. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? was written by Leow, Alex H.-R.;Azmi, Ahmad N.;Loke, Mun-Fai;Vadivelu, Jamuna;Graham, David Y.;Goh, Khean-Lee. And the article was included in Journal of Digestive Diseases in 2018.Category: imidazoles-derivatives The following contents are mentioned in the article:

The 7-day standard triple therapy (STT) gives unacceptablly low eradication rates of Helicobacter pylori (H. pylori). We aimed to examine whether extending STT from 7 days to 14 days or adding a bismuth compound to a 7-day STT would result in better eradication rates. H. pylori-pos. patients were assigned to Group A (7-day STT; rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily, for 7 days), Group B (7-day STT with bismuth; rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily and bismuth subcitrate 240 mg twice daily, for 7 days) and Group C (14-day STT; rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily for 14 days). Eradication was tested using ¹³C-UBT at least 4 wk after the completion of therapy. A total of 364 patients were recruited. In the intention-to-treat anal., eradication rates were 79.3% (96/121; 95% confidence interval [CI] 71.3-85.6%) for 7-day STT, 81.7% (98/120; 95% CI 73.8-87.6%) for 7-day STT with bismuth, and 88.6% (109/123; 95% CI 81.8-93.1%) for 14-day STT, resp. Statistical significance was achieved between the 7-day and the 14-day STT treatment (P = 0.048). Adding bismuth to the 7-day STT did not result in an increase in the eradication rate. Extending the STT to 14 days, however, achieved a significantly higher eradication rate. Nevertheless, this did not achieve the targeted 90% eradication rate on intention-to-treat anal. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Category: imidazoles-derivatives).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas was written by Dimou, Maria;Papageorgiou, Sotirios G.;Stavroyianni, Niki;Katodritou, Eirini;Tsirogianni, Maria;Kalpadakis, Christina;Banti, Anastasia;Arapaki, Maria;Iliakis, Theodoros;Bouzani, Maria;Verrou, Eugenia;Spanoudakis, Emmanouil;Giannouli, Stavroula;Marinakis, Theodoros;Mandala, Evdokia;Mparmparousi, Despoina;Sachanas, Sotirios;Dalekou-Tsolakou, Maria;Hatzimichael, Eleftheria;Vadikolia, Chryssa;Violaki, Vasiliki;Poziopoulos, Christos;Tsirkinidis, Pantelis;Chatzileontiadou, Sofia;Vervessou, Elissavet;Ximeri, Maria;Sioni, Anastasia;Konstantinidou, Pavlina;Kyrtsonis, Marie-Christine;Siakantaris, Marina P.;Angelopoulou, Maria K.;Pappa, Vassiliki;Konstantopoulos, Kostas;Panayiotidis, Panayiotis;Vassilakopoulos, Theodoros P.. And the article was included in Hematological Oncology in 2021.Reference of 16506-27-7 The following contents are mentioned in the article:

Transplant-ineligible relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADG), with bendamustine- rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on the GO29365 phase IIb trial. Real-life data with Pola are extremely limited. We report the outcomes of 61 Greek patients, who received Pola-(B)R mainly within a compassionate use program. Treatment was given for up to six 21-day cycles. Bendamustine was omitted in three cases due to previous short-lived responses. Fourty-nine rrDLBCL(efficacy cohort-EC) and 58 rr aggressive B-NHL (safety cohort-SC) patients received at least 1 Pola-BR cycle. Twenty-one (43%) patients of the EC responded with 12/49 (25%) CR and 9/49 (18%) PR as best response. Median progression-free survival, overall survival and duration of response were 4.0, 8.5, and 8.5 mo resp., while 55% of patients experienced a grade � adverse event, mainly hematol. Treatment discontinuations and death during treatment were mainly due to disease progression. Twenty-two (41%) patients received further treatment; 11/22 are still alive, including one after CAR-T cells, and two after stem cell transplantation. Our data confirm that Pola-BR is a promising treatment for rrDLBCL patients, inducing an adequate response rate with acceptable toxicity. Pola-BR could be used as bridging therapy before further consolidative treatments. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Formulation development & evaluation of buffered tablet of proton pump inhibitors drug rabeprazole sodium was written by Kumari, Mamta;Jain, Nishi Prakash. And the article was included in Journal of Drug Delivery and Therapeutics in 2019.Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

The aim of present study was to prepare buffered tablets of acid labile drug, Rabeprazole sodium for oral administration using buffering agents to protect a drug from gastric fluid. Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+, K+ATPase at the secretory surface of the gastric parietal cell. Rabeprazole blocks the final step of gastric acid secretion. The tablets were prepared by direct compression and wet granulation method. The formulations contain water soluble buffers such as sodium bicarbonate and trisodium phosphate as well as water insoluble buffers as magnesium oxide, magnesium hydroxide and calcium carbonate and crospovidone as superdisintegrant. Preformulation studies like angle of repose, bulk d., tapped d., Carr’s index, hausner’s ratios, DSC and drug/excipient compatibility study were conducted and evaluated for hardness, friability, weight variation, drug content, disintegration and in-vitro dissolution In the present study, pH of F6 batch was found to be optimum and disintegration time is 42 s. The drug release was found to show maximum drug release in case of F6 with 99.3% in 60 min. In case of stability studies study of the optimized batch, all the results were found to be satisfactory and within limits. There were no significant changes after the period of 1 mo study. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Safety of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem